Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Target FSHD
NCT06721299Phase 1Recruiting
- Start
- Jun 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of clenbuterol in facioscapulohumeral muscular dystrophy (FSHD) (3 cohorts). Primary endpoints: Frequency of Clenbuterol-related adverse reactions at 6 months, Change in heart rate at 6 months and 6 more. Started Jun 2025; status: recruiting.
02
Drugs
clenbuterol
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NCT06721299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06721299.